MARKET

VERA

VERA

Vera Therapeutics, Inc.
NASDAQ
38.86
-1.40
-3.48%
After Hours: 38.00 -0.86 -2.21% 18:10 03/27 EDT
OPEN
39.88
PREV CLOSE
40.26
HIGH
40.47
LOW
38.17
VOLUME
763.19K
TURNOVER
--
52 WEEK HIGH
56.05
52 WEEK LOW
18.53
MARKET CAP
2.77B
P/E (TTM)
-8.3312
1D
5D
1M
3M
1Y
5Y
1D
*Vera Therapeutics: Announces Inducement Grants Under Nasdaq Listing Rule
Dow Jones · 11h ago
Vera Therapeutics grants 56,850 stock options at $40.73; issues 42,403 RSUs under 2024 Inducement Plan
Reuters · 11h ago
VERA THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11h ago
Vera Therapeutics files initial beneficial ownership statement; Chief Legal Officer Jane Wright-Mitchell reports no securities beneficially owned
Reuters · 2d ago
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Reuters · 2d ago
Press Release: Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Dow Jones · 2d ago
Weekly Report: what happened at VERA last week (0316-0320)?
Weekly Report · 4d ago
Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)
TipRanks · 03/17 12:30
More
About VERA
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. It is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. It retains all global developmental and commercial rights to atacicept and MAU868.

Webull offers Vera Therapeutics, Inc stock information, including NASDAQ: VERA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VERA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VERA stock methods without spending real money on the virtual paper trading platform.